The Pharmaletter

One To Watch

coya-tx-large

Coya Therapeutics

A clinical-stage biotech company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (tregs) to target systemic inflammation and neuroinflammation.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs.

The company's platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages.

Want to Update your Company's Profile?


More Coya Therapeutics news >